Arnold & Porter Advises Mayne Pharma on US$604M Acquisition by Gedeon Richter
Arnold & Porter advised Mayne Pharma Group Ltd., an Australia-based pharmaceutical company focused on women’s health and dermatology in the United States, on its acquisition by Hungarian pharmaceutical company Gedeon Richter Plc.
Under the proposed agreement, Richter will acquire all outstanding shares of Mayne Pharma for $6.40 per share, valuing the transaction at approximately US$604 million. The transaction is expected to close in March 2027, subject to shareholder, court, and regulatory approvals, and to the completion of the sale of Mayne Pharma’s international business to Evaris Pharma.
The Arnold & Porter team was led by Derek Stoldt, partner and co-chair of the firm's Corporate and Finance group, as well as partners Tracy Belton, Debbie Feinstein, Aaron Miner, and Soo-Mi Rhee, counsel Kathleen Wechter, senior associates Greg Criscitello, Claire Frost, and Kathryn Geoffroy, and associate Bell Johnson.